Identification of inhibitors to papillomavirus type 16 E6 protein based on three-dimensional structures of interacting proteins

James D. Baleja, Jonathan J. Cherry, Zhiguo Liu, Hua Gao, Marc C. Nicklaus, Johannes H. Voigt, Jason J. Chen, Elliot Androphy

Research output: Contribution to journalArticle

41 Citations (Scopus)

Abstract

Human papillomaviruses (HPV) cause cutaneous and genital warts. A subset of HPV types is associated with a high-risk for progression to malignancy. The E6 protein from the high-risk HPV types represents an attractive target for intervention because of its roles in viral propagation and cellular transformation. E6 functions in part by interaction with human cellular proteins, several of which possess a helical E6-binding motif. The role for each amino acid in this motif for binding E6 has been tested through structure determination and site-directed mutagenesis. These structural and molecular biological approaches defined the spatial geometry of functional groups necessary for binding to E6. This E6-binding information (the E6-binding pharmacophore) was transferred into a three-dimensional query format suitable for computational screening of large chemical databases. Compounds were identified and tested using in vitro and cell culture-based assays. Several compounds selectively inhibited E6 interaction with the E6-binding protein E6AP and interfered with the ability of E6 to promote p53 degradation. Such compounds provide leads for the development of new pharmacologic agents to treat papillomavirus infections and their associated cancers.

Original languageEnglish (US)
Pages (from-to)49-59
Number of pages11
JournalAntiviral Research
Volume72
Issue number1
DOIs
StatePublished - Oct 2006
Externally publishedYes

Fingerprint

Proteins
Chemical Databases
Condylomata Acuminata
Amino Acid Motifs
Papillomavirus Infections
Site-Directed Mutagenesis
Neoplasms
Carrier Proteins
Cell Culture Techniques
Skin
In Vitro Techniques

Keywords

  • Antiviral
  • E6
  • HPV-16
  • In silico screening
  • Papillomavirus
  • Protein-protein interaction

ASJC Scopus subject areas

  • Virology
  • Pharmacology

Cite this

Identification of inhibitors to papillomavirus type 16 E6 protein based on three-dimensional structures of interacting proteins. / Baleja, James D.; Cherry, Jonathan J.; Liu, Zhiguo; Gao, Hua; Nicklaus, Marc C.; Voigt, Johannes H.; Chen, Jason J.; Androphy, Elliot.

In: Antiviral Research, Vol. 72, No. 1, 10.2006, p. 49-59.

Research output: Contribution to journalArticle

Baleja, James D. ; Cherry, Jonathan J. ; Liu, Zhiguo ; Gao, Hua ; Nicklaus, Marc C. ; Voigt, Johannes H. ; Chen, Jason J. ; Androphy, Elliot. / Identification of inhibitors to papillomavirus type 16 E6 protein based on three-dimensional structures of interacting proteins. In: Antiviral Research. 2006 ; Vol. 72, No. 1. pp. 49-59.
@article{c22b70edfc9f47b5be4de4ad34f6fcaa,
title = "Identification of inhibitors to papillomavirus type 16 E6 protein based on three-dimensional structures of interacting proteins",
abstract = "Human papillomaviruses (HPV) cause cutaneous and genital warts. A subset of HPV types is associated with a high-risk for progression to malignancy. The E6 protein from the high-risk HPV types represents an attractive target for intervention because of its roles in viral propagation and cellular transformation. E6 functions in part by interaction with human cellular proteins, several of which possess a helical E6-binding motif. The role for each amino acid in this motif for binding E6 has been tested through structure determination and site-directed mutagenesis. These structural and molecular biological approaches defined the spatial geometry of functional groups necessary for binding to E6. This E6-binding information (the E6-binding pharmacophore) was transferred into a three-dimensional query format suitable for computational screening of large chemical databases. Compounds were identified and tested using in vitro and cell culture-based assays. Several compounds selectively inhibited E6 interaction with the E6-binding protein E6AP and interfered with the ability of E6 to promote p53 degradation. Such compounds provide leads for the development of new pharmacologic agents to treat papillomavirus infections and their associated cancers.",
keywords = "Antiviral, E6, HPV-16, In silico screening, Papillomavirus, Protein-protein interaction",
author = "Baleja, {James D.} and Cherry, {Jonathan J.} and Zhiguo Liu and Hua Gao and Nicklaus, {Marc C.} and Voigt, {Johannes H.} and Chen, {Jason J.} and Elliot Androphy",
year = "2006",
month = "10",
doi = "10.1016/j.antiviral.2006.03.014",
language = "English (US)",
volume = "72",
pages = "49--59",
journal = "Antiviral Research",
issn = "0166-3542",
publisher = "Elsevier",
number = "1",

}

TY - JOUR

T1 - Identification of inhibitors to papillomavirus type 16 E6 protein based on three-dimensional structures of interacting proteins

AU - Baleja, James D.

AU - Cherry, Jonathan J.

AU - Liu, Zhiguo

AU - Gao, Hua

AU - Nicklaus, Marc C.

AU - Voigt, Johannes H.

AU - Chen, Jason J.

AU - Androphy, Elliot

PY - 2006/10

Y1 - 2006/10

N2 - Human papillomaviruses (HPV) cause cutaneous and genital warts. A subset of HPV types is associated with a high-risk for progression to malignancy. The E6 protein from the high-risk HPV types represents an attractive target for intervention because of its roles in viral propagation and cellular transformation. E6 functions in part by interaction with human cellular proteins, several of which possess a helical E6-binding motif. The role for each amino acid in this motif for binding E6 has been tested through structure determination and site-directed mutagenesis. These structural and molecular biological approaches defined the spatial geometry of functional groups necessary for binding to E6. This E6-binding information (the E6-binding pharmacophore) was transferred into a three-dimensional query format suitable for computational screening of large chemical databases. Compounds were identified and tested using in vitro and cell culture-based assays. Several compounds selectively inhibited E6 interaction with the E6-binding protein E6AP and interfered with the ability of E6 to promote p53 degradation. Such compounds provide leads for the development of new pharmacologic agents to treat papillomavirus infections and their associated cancers.

AB - Human papillomaviruses (HPV) cause cutaneous and genital warts. A subset of HPV types is associated with a high-risk for progression to malignancy. The E6 protein from the high-risk HPV types represents an attractive target for intervention because of its roles in viral propagation and cellular transformation. E6 functions in part by interaction with human cellular proteins, several of which possess a helical E6-binding motif. The role for each amino acid in this motif for binding E6 has been tested through structure determination and site-directed mutagenesis. These structural and molecular biological approaches defined the spatial geometry of functional groups necessary for binding to E6. This E6-binding information (the E6-binding pharmacophore) was transferred into a three-dimensional query format suitable for computational screening of large chemical databases. Compounds were identified and tested using in vitro and cell culture-based assays. Several compounds selectively inhibited E6 interaction with the E6-binding protein E6AP and interfered with the ability of E6 to promote p53 degradation. Such compounds provide leads for the development of new pharmacologic agents to treat papillomavirus infections and their associated cancers.

KW - Antiviral

KW - E6

KW - HPV-16

KW - In silico screening

KW - Papillomavirus

KW - Protein-protein interaction

UR - http://www.scopus.com/inward/record.url?scp=33747881135&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33747881135&partnerID=8YFLogxK

U2 - 10.1016/j.antiviral.2006.03.014

DO - 10.1016/j.antiviral.2006.03.014

M3 - Article

VL - 72

SP - 49

EP - 59

JO - Antiviral Research

JF - Antiviral Research

SN - 0166-3542

IS - 1

ER -